A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Study ID
- NCT05820672
- Status
- Recruiting
Conditions
- Growth Hormone Deficiency
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- No intervention — OTHERNo intervention
Study Details
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Key Dates
- Start date
- Mar 20, 2023
- Status verified
- Apr 2026
- Primary completion
- Mar 31, 2033
- Completion
- Mar 31, 2033
Study Design
- Enrollment
- 900 participants (estimated)
Arms
- Arm: Patients on SKYTROFA TreatmentPatients on SKYTROFA Treatment managed in USA with appropriate written Informed Consent
Primary Outcome Measure
Assess the safety of patients treated with SKYTROFA (Lonapegsomatropin) [ Time Frame: 5 years ]
Central Contacts
- Deborah Bowlby+1 844-442-7236
Locations (27)
Find similar trials in Phoenix, AZ
Related Studies
- Chromosome 18 Clinical Research CenterRecruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
- Effects of GH and Lirglutide on AgRPPHASE4 · Recruiting · Columbia University · New York, New York
- A Post-Authorisation Safety Study (PASS) of Patients Treated With LonapegsomatropinRecruiting · Ascendis Pharma Endocrinology Division A/S · Phoenix, Arizona
- A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)PHASE2 · Enrolling By Invitation · Lumos Pharma · Iowa City, Iowa